A Phase 3 interventional study of Brivaracetam Film-coated tablet and Brivaracetam oral solution in Childhood Absence Epilepsy and Juvenile Absence Epilepsy, sponsored by UCB Biopharma SRL. Completed at 24 sites in 6 countries. Open to participants aged 2 Years to 26 Years. Per ClinicalTrials.gov, last updated 2025-10-22.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
24 studies on the registry are indexed under Epilepsy, Absence; 2 are open to participants now.
This study's enrollment of 84 is above the median of 20 across 17 interventional studies indexed under Epilepsy, Absence.
Browse Epilepsy, Absence studies →UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
Drug: Brivaracetam Film-coated tablet · Drug: Brivaracetam oral solution
* Pharmaceutical form: Film-coated tablet * Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
* Pharmaceutical form: Oral solution * Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV.
Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Percentage of participants with TEAEs leading to discontinuation were reported.
Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Percentage of Participants With Serious TEAEs
TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, results in permanent or significant disability/incapacity, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.
Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Percentage of Participants With Study Drug-related TEAEs
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Drug related AEs are the subset of AEs that the investigator considers as related to the study drug.
Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Percentage of Participants With Absence Seizure Freedom Within 4 Days Prior to or During the 1-hour Electroencephalogram (EEG)
A 1-hour EEG was performed. The awake hours from the EEG was analyzed for absence seizures. Every 1-hour EEG included hyperventilation as a standard provocation test at the beginning of the EEG. Participant was regarded as not meeting the criteria for absence seizure freedom if they received any permitted antiepileptic drugs including benzodiazepine in the 4 days prior to the EEG or during the EEG. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 yearly evaluation visit (YEV).
Time frame: Full Evaluation Visit (6 months), Yearly Evaluation Visit (12 months), Full Evaluation Visit (18 months), Yearly Evaluation Visit (24 months)
Percentage of Participants With Absence Seizure Freedom Based on Daily Seizure Diary Over the Entire Evaluation Period and by 3-month Time Intervals
During the study, participants kept a diary to record daily seizure activity from entry visit (Visit 1) until the final visit. Each seizure type experienced were recorded. The participant was considered as not meeting the criteria for absence seizure freedom if they use any permitted anti-epileptic drugs at anytime during the period, and/or complete less than 80% of diaries during the period. Evaluation Period includes all daily seizure diary data over the Evaluation Period up to Month 24 YEV, this includes data from the end of Months 22 to 24 up to the Month 24 YEV where this data is truncated. If a participant does not attend the Month 24 YEV then data was truncated at the last day the participant is in the Evaluation Period in the Month 24 YEV window. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 YEV, or the last day the participant was in the Evaluation Period in the Month 24 YEV window if this visit is not attended.
Time frame: Months 1-3, Months 4-6, Months 7-9, Months 10-12, Months 13-15, Months 16-18, Months 19-21, Months 22-24 and Entire Evaluation Period (Up to 24 months)
The study started to enroll participants in March 2022 and concluded in March 2025.
| Milestone | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Started | 64 | 20 |
| Evaluation period (up to 24 months) | 64 | 20 |
| Completed | 50 | 14 |
| Not completed | 14 | 6 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lack of efficacy | 5 | 0 |
| Withdrew: Consent withdrawn by participant (not due to ae) | 1 | 0 |
| Withdrew: Consent withdrawn by parent/guardian (not ae) | 3 | 4 |
| Withdrew: Evacuated from ukraine due to the war | 2 | 0 |
| Withdrew: Missed safety visit; study incomplete per protocol | 1 | 0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV.
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | 42.2 | 55.0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Percentage of participants with TEAEs leading to discontinuation were reported.
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment | 3.1 | 10.0 |
TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, results in permanent or significant disability/incapacity, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Percentage of Participants With Serious TEAEs | 3.1 | 10.0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Drug related AEs are the subset of AEs that the investigator considers as related to the study drug.
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Percentage of Participants With Study Drug-related TEAEs | 6.3 | 10.0 |
A 1-hour EEG was performed. The awake hours from the EEG was analyzed for absence seizures. Every 1-hour EEG included hyperventilation as a standard provocation test at the beginning of the EEG. Participant was regarded as not meeting the criteria for absence seizure freedom if they received any permitted antiepileptic drugs including benzodiazepine in the 4 days prior to the EEG or during the EEG. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 yearly evaluation visit (YEV).
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| FEV: 6 months | 46.4 | 70.0 |
| YEV: 12 months | 42.6 | 44.4 |
| FEV: 18 months | 38.9 | 50.0 |
| YEV: 24 months | 26.7 | 18.2 |
During the study, participants kept a diary to record daily seizure activity from entry visit (Visit 1) until the final visit. Each seizure type experienced were recorded. The participant was considered as not meeting the criteria for absence seizure freedom if they use any permitted anti-epileptic drugs at anytime during the period, and/or complete less than 80% of diaries during the period. Evaluation Period includes all daily seizure diary data over the Evaluation Period up to Month 24 YEV, this includes data from the end of Months 22 to 24 up to the Month 24 YEV where this data is truncated. If a participant does not attend the Month 24 YEV then data was truncated at the last day the participant is in the Evaluation Period in the Month 24 YEV window. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 YEV, or the last day the participant was in the Evaluation Period in the Month 24 YEV window if this visit is not attended.
| percentage of participants | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Months 1-3 | 34.4 | 35.0 |
| Months 4-6 | 39.0 | 55.0 |
| Months 7-9 | 37.7 | 57.9 |
| Months 10-12 | 38.8 | 55.6 |
| Months 13-15 | 31.8 | 61.1 |
| Months 16-18 | 35.9 | 56.3 |
| Months 19-21 | 30.3 | 42.9 |
| Months 22-24 | 21.9 | 33.3 |
| Entire Evaluation Period (up to 24 months) | 28.1 | 30.0 |
Collected over From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Childhood Absence Epilepsy (CAE): Brivaracetam | 0/64 (0%) | 2/64 (3.1%) | 15/64 (23.4%) |
| Juvenile Absence Epilepsy (JAE): Brivaracetam | 0/20 (0%) | 2/20 (10%) | 8/20 (40%) |
| Event | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| MeaslesInfections and infestations | 0/64 | 1/20 |
| Generalised tonic-clonic seizureNervous system disorders | 0/64 | 1/20 |
| Status epilepticusNervous system disorders | 0/64 | 1/20 |
| LymphadenitisBlood and lymphatic system disorders | 1/64 | 0/20 |
| Suicidal ideationPsychiatric disorders | 1/64 | 0/20 |
| Event | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam |
|---|---|---|
| Petit mal epilepsyNervous system disorders | 9/64 | 5/20 |
| PyrexiaGeneral disorders | 4/64 | 4/20 |
| HeadacheNervous system disorders | 3/64 | 2/20 |
The SS consisted of all enrolled study participants who took at least 1 dose of study drug in the long-term follow-up (LTFU) study.
| Age, Continuous(years) | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam | Total |
|---|---|---|---|
| Mean | 9.56 ± 2.49 | 13.93 ± 1.64 | 10.60 ± 2.97 |
| Age, Customized(Participants) | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam | Total |
|---|---|---|---|
| 24 months - <12 years | 53 | 2 | 55 |
| 12 - <18 years | 11 | 18 | 29 |
| Sex: Female, Male(Participants) | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam | Total |
|---|---|---|---|
| Female | 37 | 11 | 48 |
| Male | 27 | 9 | 36 |
| Race/Ethnicity, Customized(Participants) | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam | Total |
|---|---|---|---|
| Race — Asian | 1 | 0 | 1 |
| Race — Black or African American | 5 | 0 | 5 |
| Race — White | 57 | 20 | 77 |
| Race — Other or Mixed | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Childhood Absence Epilepsy (CAE): Brivaracetam | Juvenile Absence Epilepsy (JAE): Brivaracetam | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 5 | 0 | 5 |
| Ethnicity — Not Hispanic or Latino | 59 | 20 | 79 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · vivli.org
Ran from Mar 2022 to primary completion in Mar 2025, 35 months.
Results were first posted in Oct 2025, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam